nidan7500 Saturday, 07/27/19 08:53:01 AM Re: XenaLives post# 203541 Post # of 236946 Xena Quote:The consortium trial is for the purpose of establishing biomarkers for schizophrenia, so a "normal" and a diagnosed population will have data collected, it will be analyzed with AI and ERP patterns will be identified that can be used to objectively evaluate disease severity and drug response. After these biomarkers are determined a single arm trial could be short and sweet. We are on the same page here. Only a matter of time until these tools and the WW power of CNS diseases clinical db management starts to flourish. Until now there has been almost no CNS disease effective treatments to even cause researchers to think along these lines. (why bother develop tools when nothing works) The concept of establishing CNS cellular Homeostasis presents challenges which will now be critically and objectively and accurately be measured using ERP or equivalent tools and methods. IMO, between these tools w/the capability to accurately measure and use compiled CNS treatment data ...THEY GOT THIS. Would be great to be in school w/this kind of challenge. Like fish in a barrel. Dr.M. and team don't say much but lets hope they let the science do the talking around here.